Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer - Wikidata - awgldk - TriplyDB

Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer

Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer

http://www.wikidata.org/entity/Q33401352

about

A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.Regorafenib: from bench to bedside in colorectal cancer.Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?

P2860

Q33440392-937295A5-FDFD-488F-80BD-B7E8A02C5D84 Q34343524-D858CB59-F9EF-48B9-B504-6F05FFC2D619 Q35183062-851157EA-7344-4413-B3FF-204642F9F4A4 Q36270115-816A2E19-6B3B-49BB-B7C7-DC1BF03F2C26 Q37632102-3A85E43F-DA7F-4DEE-9D17-DF8F1CBFFE96 Q38166233-B8665997-8561-400E-AF39-ECE50191403E Q38672966-49CCE1AC-0B85-4FA4-9425-D48F0DB2A3C2

P2860

Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer

http://www.wikidata.org/entity/Q33401352

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase I pharmacokinetic and ph ...... in advanced colorectal cancer

@ast

Phase I pharmacokinetic and ph ...... in advanced colorectal cancer

@en

type

label

Phase I pharmacokinetic and ph ...... in advanced colorectal cancer

@ast

Phase I pharmacokinetic and ph ...... in advanced colorectal cancer

@en

prefLabel

Phase I pharmacokinetic and ph ...... in advanced colorectal cancer

@ast

Phase I pharmacokinetic and ph ...... in advanced colorectal cancer

@en

P1433

Q33401352-B741AA8E-D7B1-4F54-ACC3-A8721838C843

P1476

Q33401352-D261B4AF-836C-451A-BA7D-B1591B203447

P2093

Q33401352-05AA8847-63A8-4D35-AB34-64002A55AD9E

Q33401352-0D8F739E-06DE-4014-940B-074CC03168D7

Q33401352-3D8308B8-A80B-4FDD-A2DA-A7D32C95CE6A

Q33401352-49117E53-6198-4B05-BA2B-524C5076A8FB

Q33401352-5073C167-9D63-4109-8E57-981656D85458

Q33401352-58209940-5C72-45CC-B2DD-0A38338A9DF3

Q33401352-6869FFDD-B565-4519-962B-F5DD554B6543

Q33401352-84480FAF-38CD-482D-9BB3-672A717D9A7B

Q33401352-8FFE88CF-B002-4BBA-A7A3-22E01CBD8225

Q33401352-9353C3F5-8DBF-431B-BFD6-B838AF42698C

P2860

Q33401352-04AF1E0D-4C25-43BC-B6A6-FB922975379D

Q33401352-05B368FA-5038-49EE-B25D-9AAE07E53392

Q33401352-0B9148BC-553B-4C83-B1B0-4ABA186A128F

Q33401352-18B16303-6D0E-45AC-8D69-95DF83164764

Q33401352-25354615-D5D8-43B7-B4DD-E2AA2460A302

Q33401352-2FD341E1-C524-42C1-AECF-86EB712580ED

Q33401352-302487E0-A556-47CA-ADB9-CDABABC84E1F

Q33401352-340107D0-68B2-4847-9446-F15786C54001

Q33401352-3852AA0E-BC49-4126-8D1B-536D52586095

Q33401352-480FECA8-AB77-4221-BE64-6380E2EDB052

P2888

Q33401352-0848C593-34D2-45CD-8640-59F5EE6C783B

P304

Q33401352-FA880DE3-779F-48F9-BE93-0650475F099A

P31

Q33401352-22FB3F0E-E056-4B11-95AD-CFAD9FECD4DB

P356

Q33401352-32E6D2FF-926C-4360-93FE-B61BAA585B6D

P433

Q33401352-4A8778A2-BF15-4695-A60A-985092659D80

P478

Q33401352-B34A136E-E226-4B3A-8C53-8B9F78388255

P50

Q33401352-0825A93A-D711-4CF1-80F0-5D89105C0DBA

Q33401352-8E18E330-8A11-43F6-8CFB-40C99C2772D4

P577

Q33401352-69FC4332-5C58-4FF0-BA4E-338FA246A429

P6179

Q33401352-18398872-C665-4022-A112-054D9E523909

P698

Q33401352-6244F32A-F8B4-4FEA-AE23-6B8F2BCA03DD

P921

Q33401352-5E6E9A67-3917-4650-ACDC-4AFF70BD4348

Q33401352-63FF4CB2-8F6E-46DE-8F77-394885E5E4E3

P932

Q33401352-A732B3B4-DE54-467A-859B-5AFCFBF934D7

P356

S10637-012-9820-Z

P1433

Investigational New Drugs

P1476

Phase I pharmacokinetic and ph ...... in advanced colorectal cancer

@en

P2093

Arvind Dasari

http://www.w3.org/2001/XMLSchema#string

Daniel A Laheru

http://www.w3.org/2001/XMLSchema#string

Gretchen E Taylor

http://www.w3.org/2001/XMLSchema#string

John Arcaroli

http://www.w3.org/2001/XMLSchema#string

John J Wright

http://www.w3.org/2001/XMLSchema#string

Kevin Quackenbush

http://www.w3.org/2001/XMLSchema#string

Martine McManus

http://www.w3.org/2001/XMLSchema#string

Michael A Carducci

http://www.w3.org/2001/XMLSchema#string

Michelle A Rudek

http://www.w3.org/2001/XMLSchema#string

Ming Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

P2888

s10637-012-9820-z

P304

345-354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-012-9820-Z

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Luis Alberto Diaz Jr

P577

2012-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1012639474

http://www.w3.org/2001/XMLSchema#string

P698

22615057

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3674958

http://www.w3.org/2001/XMLSchema#string